Assessment of a 60-biomarker health surveillance panel (HSP) on whole blood from remote sampling devices by targeted LC/MRM-MS and discovery DIA-MS analysis

Abstract

SummaryTelehealth, accessing healthcare and wellness remotely, should be a cost effective and efficient way for individuals to receive care. The convenience of having a robust remote collection device for blood tests will facilitate access to precision medicine and healthcare. Herein, we tested a 60-biomarker health surveillance panel (HSP), containing 35 FDA/LDT assays and covering at least 14 pathological states, on 8 healthy individuals’ ability to collect their own capillary blood from a lancet finger prick and directly compared to the traditional phlebotomist venous blood and plasma collection methods. Samples were quantitatively analyzed by a liquid chromatography-multiple reaction monitoring-mass spectrometry method targeting 114 peptides representing 60 HSP proteins and by a data-independent acquisition mass spectrometry discovery method, resulting in up to 3,811 protein identifications including 122 FDA approved biomarkers. The >90% similarity between the three biofluids indicate that remote collection devices are a viable option for personal blood proteome biosignature stratification and health analysis.